- Home
- BIVI
BIVI
BioVie Inc.
as 07-26-2024 4:00pm EST
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CARSON CITY |
| Market Cap: | 27.1M | IPO Year: | N/A |
| Target Price: | $6.33 | AVG Volume (30 days): | 775.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.34 - $5.82 | Next Earning Date: | 08-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of BioVie Inc. (BIVI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DO CUONG V | BIVI | President & CEO | Nov 30 '23 | Buy | $1.78 | 10,000 | $17,800.00 | 68,759 | SEC Form 4 |
| GORLIN STEVE | BIVI | Director | Nov 9 '23 | Sell | $1.69 | 75,680 | $127,899.20 | 46,358 | SEC Form 4 |
Latest BioVie Inc. News
BIVI Breaking Stock News: Dive into BIVI Ticker-Specific Updates for Smart Investing
ACCESSWIRE
21 days ago
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
a month ago
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
ACCESSWIRE
a month ago
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
a month ago
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
GlobeNewswire
a month ago
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
GlobeNewswire
2 months ago
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
GlobeNewswire
2 months ago
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
MT Newswires
3 months ago
BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID
Compare BIVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIVI BioVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.